Please assess the completion status of the following clinical trial:

Trial Title: Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Increased risk of SARS-CoV-2 infection~* Medically stable~Exclusion Criteria:~* confirmed or suspected immunosuppressive or immunodeficient state~* significant disease, disorder, or finding~* Prior or concomitant vaccine therapy for COVID-19

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: t

Study Arms:
- AZD1222 (Type: EXPERIMENTAL): Approximately 20,000 participants randomized to the AZD1222 arm
- Placebo (Type: PLACEBO_COMPARATOR): Approximately 10,000 participants randomized to the saline placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).